High Grade Ovarian Cancer research hub
10 indexed studies · 5 currently recruiting
- active not recruitingPHASE2
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
This study looks at a new drug, mirvetuximab soravtansine, with carboplatin for certain types of ovarian, primary peritoneal, or fallopian tube cancer. It's for people whose cancer has come back but responded well to previous platinum-based chemotherapy.
United States · Belgium · Canada - recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
This study looks at a new treatment called sacituzumab tirumotecan, sometimes with another medicine called bevacizumab. We want to see if it's safe and helps women with ovarian, fallopian tube, or primary peritoneal cancer live longer without their cancer getting worse, compared to standard care.
United States · Argentina · Australia - recruitingPHASE2
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
This study is for women with ovarian cancer that has come back, specifically a type that has responded well to chemotherapy in the past. It's looking at a new way to give carboplatin, a common chemotherapy drug, to see if it can work better and with fewer side effects.
United Kingdom - active not recruitingPHASE3
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
This study is for women with advanced ovarian cancer who've had their first treatment. It's testing if two medications, rucaparib and nivolumab, given after initial treatment, can help prevent the cancer from returning or growing. It compares these drugs to dummy treatments.
United States · Australia · Belgium - active not recruitingPHASE3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
This study is looking at a new treatment for certain types of ovarian, fallopian tube, or peritoneal cancer that have returned after initial treatment. It compares a new drug, mirvetuximab soravtansine, given with bevacizumab, against bevacizumab alone, to see if the new combination can keep the cancer away for longer.
United States · Argentina · Australia - active not recruitingPHASE2
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
This study looks at giving olaparib, a new drug, before surgery and chemotherapy for recurrent ovarian, primary peritoneal, or fallopian tube cancer. It aims to see if it can shrink tumours and improve outcomes.
Canada · New Zealand · Spain - active not recruitingPHASE1
"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This study is for women with advanced ovarian, fallopian tube, or peritoneal cancer that has come back and isn’t responding to standard chemotherapy. It’s testing a new approach using special immune cells from your own body, called TILs, along with other treatments to see if they can fight the cancer.
Canada - recruitingPHASE2
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
The CATALINA-2 study is investigating a new drug called TORL-1-23 for women with advanced ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to platinum-based chemotherapy. It aims to see how safe and effective this new treatment is.
United States · Australia · Austria - recruitingPHASE3
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
This study compares two ways to treat advanced ovarian cancer: standard chemotherapy plus a medicine called niraparib, versus standard chemotherapy plus two medicines, bevacizumab and niraparib. It aims to see which treatment works best to control the cancer.
Germany - recruitingPHASE1, PHASE2
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This study is testing a new drug, ART0380, for people with advanced cancer. It aims to find the safest dose, understand side effects, and see how well it works, both alone and with other treatments like gemcitabine or irinotecan.
United States · France · Spain